Thank you for your reply and the useful references.
I realize from these papers that FRA3B/FHIT site participates in cancer pathophysiology, but they do not clearly say that people who constitutionally show FRA3B in their blood cultures are neccessarily more susceltible to cancer. What do you think?
I emailed Professor Huebner. She told me that the number of cells with FRA3B in our case (30% of examined cells) is pretty significant and serum FHIT level should be checked.
We are going to take the history of the patient (as soon as he respond to our calls) and ask him to come and give us another specimen, not only to repeat the karyotype but also to get his serum.